LRMR
Income statement / Annual
Last year (2025), Larimar Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Larimar Therapeutics Inc's net income was -$165.67 M.
See Larimar Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$155.00 K
|
$78.00 K
|
$261.00 K
|
$188.00 K
|
$212.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$155.00 K
|
-$78.00 K
|
-$261.00 K
|
-$188.00 K
|
-$212.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$154.22 M
|
$73.28 M
|
$27.67 M
|
$24.25 M
|
$38.40 M
|
$31.25 M
|
$20.79 M
|
$49.53 M
|
$41.74 M
|
$39.77 M
|
| General & Administrative Expenses |
$18.27 M
|
$17.61 M
|
$14.09 M
|
$12.28 M
|
$12.07 M
|
$11.40 M
|
$2.42 M
|
$1.52 M
|
$12.16 M
|
$18.29 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$12.93 M
|
-$212.00 K
|
-$1.15 M
|
| Selling, General & Administrative Expenses |
$18.27 M
|
$17.61 M
|
$14.09 M
|
$12.28 M
|
$12.07 M
|
$11.40 M
|
$2.42 M
|
$12.93 M
|
$11.95 M
|
$17.14 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$82.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$172.50 M
|
$90.89 M
|
$41.76 M
|
$36.53 M
|
$50.47 M
|
$42.65 M
|
$23.21 M
|
$62.46 M
|
$53.69 M
|
$56.91 M
|
| Cost And Expenses |
$172.50 M
|
$90.89 M
|
$41.76 M
|
$36.53 M
|
$50.47 M
|
$42.80 M
|
$23.21 M
|
$62.72 M
|
$53.88 M
|
$57.12 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$996.00 K
|
$894.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$971.00 K
|
$347.00 K
|
| Depreciation & Amortization |
$350.00 K
|
$318.00 K
|
$311.00 K
|
$318.00 K
|
$326.00 K
|
$155.00 K
|
$78.00 K
|
$261.00 K
|
$188.00 K
|
$212.00 K
|
| EBITDA |
-$165.32 M |
-$80.29 M |
-$36.64 M |
-$35.04 M |
-$50.31 M |
-$42.65 M |
-$23.14 M |
-$60.81 M |
-$52.58 M |
-$57.44 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.82 M
|
$10.29 M
|
$4.81 M
|
$1.17 M
|
-$171.00 K
|
$322.00 K
|
$82.00 K
|
-$246.00 K
|
$947.00 K
|
-$1.06 M
|
| Income Before Tax |
-$165.67 M
|
-$80.60 M
|
-$36.95 M
|
-$35.36 M
|
-$50.64 M
|
-$42.48 M
|
-$23.13 M
|
-$62.97 M
|
-$52.93 M
|
-$58.18 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.60 M
|
-$900.00 K
|
-$300.00 K
|
| Net Income |
-$165.67 M
|
-$80.60 M
|
-$36.95 M
|
-$35.36 M
|
-$50.64 M
|
-$42.33 M
|
-$23.13 M
|
-$61.37 M
|
-$52.03 M
|
-$57.88 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.27 |
-1.32 |
-0.84 |
-1.33 |
-2.93 |
-3.56 |
-2.51 |
-22.85 |
-22.76 |
-25.44 |
| EPS Diluted |
-2.27 |
-1.32 |
-0.84 |
-1.33 |
-2.93 |
-3.56 |
-2.51 |
-22.85 |
-22.76 |
-25.44 |
| Weighted Average Shares Out |
$72.95 M
|
$61.26 M
|
$43.90 M
|
$25.76 M
|
$17.16 M
|
$11.88 M
|
$9.21 M
|
$2.69 M
|
$2.29 M
|
$2.27 M
|
| Weighted Average Shares Out Diluted |
$72.95 M
|
$61.26 M
|
$43.90 M
|
$25.76 M
|
$17.16 M
|
$11.88 M
|
$9.21 M
|
$2.69 M
|
$2.29 M
|
$2.27 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
